Tuesday, May 30, 2023
The University of Sydney has signed a memorandum of understanding (MoU) with Pharos Therapeutics, the Australian subsidiary of South Korean pharmaceutical company Pharos iBio.
Under the Memorandum of Understanding (MoU), the University's Drug Discovery Initiative will gain entry to Pharos iBio's exclusive AI drug development platform called Chemiverse. This partnership will enable Pharos to leverage the expertise of the University's esteemed team of researchers and utilise their cutting-edge drug discovery infrastructure.
The collaboration between Pharos and the University to leverage artificial intelligence (AI) for identifying promising compounds holds great potential for accelerating the development of treatments for cancers and rare diseases.
The development of drugs to treat diseases is a complex process. This collaboration with Pharos Therapeutics, marks the beginning of an exciting journey with the revolutionary artificial intelligence platform, Chemiverse. This partnership is set to unlock new frontiers in the field of AI and pave the way for groundbreaking advancements.
